Perioperative tyrosine kinase inhibitors for GIST: Standard... or an idea that needs further investigation?

ONCOLOGY

Volumn 23, Issue 1, 2009, Pages 65-66

  Von Mehren, Margaret ^a   Watson, James C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; LAPAROSCOPIC SURGERY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; RECURRENCE RISK; REVIEW; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; NEOADJUVANT THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 61449146247     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. DeMatteo R, Owzar K, Maki R, et al: Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001 (abstract 10079). J Clin Oncol 25(suppl 18), 2007.
2. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-l134, 2004.
3. Blanke CD, Rarikin C, von Mehren M, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 26:620-625, 2008.
4. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in advanced gastrointestinal stromal tumors after failure of imatinib: A randomized controlled trial. Lancet 368:1329-1338, 2006.
5. Debiec-Rychter M, Sciot R, Le Cesne A, et al: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006.
6. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007.
7. Eisenberg BL, Harris J, Blanke CD, et al: Phase II trial of neoadjuvant/ adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors (GIST) - early results of RTOG 0132. J Surg Oncol Oct 21, 2008.
8. Raut CP, Posner M, Desai J, et al: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325-2331, 2006.
9. Rutkowski P, Nowecki Z, Nyckowski P, et al: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93:304-311, 2006.
10. Gronchi A, Fior M, Miselli F, et al: Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 245:341-346, 2007.